Therapeuticsmd, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
TherapeuticsMD Director Tommy G. Thompson acquired 8,400 shares of common stock at $1.6703 per share in a pre-planned transaction.
NASDAQ
TherapeuticsMD Director Gail K. Naughton was granted 8,500 restricted stock units, vesting on November 3, 2028.
NASDAQ
TherapeuticsMD Director Tommy G. Thompson was granted 8,500 restricted stock units, which are set to vest on November 3, 2028.
NASDAQ
TherapeuticsMD Director Cooper C. Collins was granted 8,500 Restricted Stock Units, which will vest on November 3, 2028.
NASDAQ
TherapeuticsMD CEO Marlan D. Walker reported the acquisition of 67,492 non-qualified stock options with an exercise price of $1.15, vesting on November 3, 2025.
NASDAQ
Director Tommy G. Thompson reports purchasing 325 shares of TherapeuticsMD, Inc. at an average price of $1.0018 on April 14, 2025.
NASDAQ
TherapeuticsMD's CEO, Marlan D. Walker, purchased 490 shares of common stock at a price of $0.9985 per share on April 14, 2025.
NASDAQ
TherapeuticsMD's CEO, Marlan D. Walker, recently purchased additional shares of the company's common stock, increasing his holdings.
NASDAQ
Director Cooper C. Collins reports the acquisition of 8,500 shares of TherapeuticsMD common stock through the settlement of restricted stock units.
NASDAQ
Director Gail K. Naughton reports the acquisition and disposal of TherapeuticsMD, Inc. common stock related to the settlement of restricted stock units.
NASDAQ
Director Tommy G. Thompson received 8,500 shares of TherapeuticsMD common stock upon settlement of restricted stock units on February 18, 2025.
NASDAQ
Marlan D. Walker, CEO of TherapeuticsMD, Inc., reports the acquisition of common stock through the settlement of performance stock units (PSUs) and restricted stock units (RSUs) on February 18, 2025.
NASDAQ
Director Cooper C. Collins of TherapeuticsMD, Inc. (TXMD) acquired 4,094 shares of common stock at a weighted average price of $1.734 on August 22, 2024.
NASDAQ
Director Cooper C. Collins of TherapeuticsMD, Inc. (TXMD) purchased 1,200 shares of common stock at an average price of $1.6988 on August 21, 2024.